# Inhibrx Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Inhibrx Biosciences, Inc.). ## Overview Inhibrx Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing antibody-based therapeutics. Following the 2024 separation from its former parent, the company now centers on ozekibart (INBRX-109) and INBRX-106, with additional discovery-stage programs and no approved commercial products yet. ## Products & services • Ozekibart (INBRX-109), a clinical-stage antibody program • INBRX-106, a clinical-stage immuno-oncology program • Discovery pipeline of antibody-based therapeutic candidates • License and collaboration agreements generating non-product revenue • Preclinical and clinical development services managed through CROs/CDMOs - **Clinical-stage therapeutic candidates** (0%) — Includes ozekibart (INBRX-109) and INBRX-106, which are being advanced through clinical trials. - **Discovery pipeline** (0%) — Early-stage biologic programs and research assets not yet in clinical development. - **License and collaboration revenue** (100%) — Non-product revenue recognized from licensing and assignment agreements with partners. - **Outsourced development operations** (0%) — Clinical, manufacturing, and research activities managed through third-party CROs and CDMOs. - Ozekibart (INBRX-109) clinical-stage therapeutic candidate - INBRX-106 clinical-stage program in head and neck cancer - Discovery pipeline of biologic drug candidates - License fee revenue from collaboration agreements - Preclinical and clinical development outsourced to CROs/CDMOs ## Customers The company does not sell approved products commercially, so its current counterparties are primarily licensing partners, research collaborators, and service providers rather than end-market patients or hospitals. Its future customers would likely be healthcare providers and patients if any therapeutic candidate is approved and commercialized. Today, the business model depends on partner-funded or partner-enabled value creation rather than product sales. - **Licensing and collaboration partners** (primary) — Buy rights to programs or provide upfront/option payments tied to asset access and development milestones. - **CRO and CDMO service providers** (primary) — Support preclinical studies, clinical trials, and manufacturing scale-up for the company's pipeline. - **Future healthcare providers and patients** (emerging) — Would use the company's therapies if any candidate reaches approval and commercialization. - **Strategic acquirers or monetization partners** (emerging) — Potential buyers of ozekibart or other assets in transactions intended to unlock value. - Licensing partners that pay for rights to company assets - Research collaborators supporting pipeline development - CROs and CDMOs that provide outsourced development capacity - Future physicians, hospitals, and patients if products are approved - Potential acquirers or strategic partners for ozekibart monetization ## Geography The company is headquartered in the United States and its operations are primarily U.S.-based, including clinical development, management, and laboratory/office functions. The reports provided do not disclose meaningful country-level revenue concentration, and current revenue is limited to license fee income rather than product sales. Geography matters mainly through U.S. regulatory oversight, domestic financing conditions, and exposure to global supply-chain and tariff risks affecting outsourced manufacturing inputs. - Headquartered in the United States - Clinical and corporate operations are primarily U.S.-based - No disclosed country-level revenue concentration in the excerpts - Outsourced manufacturing and trial supply chains may span multiple countries - U.S. tariffs and trade policy can affect input costs and supply continuity ## Strategy Management is focused on advancing INBRX-106 through clinical development while evaluating alternatives to monetize ozekibart (INBRX-109) in a way that preserves tax efficiency and stockholder value. The company is also preparing for possible commercialization of approved assets, but near-term execution remains centered on clinical data generation, capital preservation, and external partnerships. - **Advance INBRX-106 clinical program** (short-term) — Clinical data is the main value driver for a pre-commercial biotech and determines future partnering or approval prospects. - **Monetize ozekibart (INBRX-109)** (short-term) — A transaction could unlock value and reduce dependence on internal funding while minimizing dilution. - **Preserve capital and operational flexibility** (medium-term) — The company has no product revenue and relies on external financing to fund R&D and corporate overhead. - Advance INBRX-106 through Phase 2/3 development - Generate clinical data to support later-stage decision-making - Evaluate monetization alternatives for ozekibart (INBRX-109) - Preserve cash through outsourced development and lean operations - Maintain optionality for future commercialization or partnering ## Risks The company faces the typical risks of a clinical-stage biotech: trial failure, regulatory setbacks, and the need for additional capital before any product revenue exists. Its specific risks also include dependence on third-party manufacturers and service providers, as well as uncertainty around any transaction to monetize ozekibart. Global trade policy, tariffs, and macro volatility can further raise development costs and disrupt supply chains. - **Clinical development and regulatory failure** [high] — INBRX-106 and ozekibart are still clinical-stage, so negative data or regulatory setbacks could materially reduce value. - **Dependence on third-party manufacturers and CROs/CDMOs** [high] — The company does not own manufacturing facilities and relies on a limited number of external providers for raw materials and clinical supply. - **Financing and dilution risk** [high] — With no commercial product revenue, the company may need additional capital to fund ongoing R&D and operations. - **Ozekibart monetization uncertainty** [medium] — A transaction may not occur, may take longer than expected, or may not deliver the intended tax or value benefits. - **Tariffs and geopolitical supply-chain disruption** [medium] — Higher import costs or supply interruptions could affect biologic raw materials and clinical trial continuity. - Clinical trial failure could eliminate pipeline value - No approved products means continued reliance on external funding - Third-party CRO/CDMO dependence can disrupt timelines and supply - Ozekibart monetization may not close or create expected value - Tariffs and trade policy can raise biologics input costs ## Accounting Revenue is currently limited to license fee income, so timing of recognition under collaboration and assignment agreements is a key accounting judgment. R&D expense is heavily influenced by outsourced clinical and manufacturing activity, while lease commitments and debt financing affect the balance sheet and cash flow profile. Because the company is pre-commercial, valuation and impairment judgments around acquired or strategic assets can also become important if transactions or pipeline changes occur. - **License fee revenue recognition** — Can create lumpy quarterly revenue from collaboration agreements - **Research and development expense timing** — Quarterly operating loss can swing with study activity and vendor timing - **Lease commitments** — Affects right-of-use assets, lease liabilities, and cash commitments - **Debt and interest expense** — Impacts liquidity, leverage, and net loss - License fee revenue recognition depends on contract milestones and transfer of rights - R&D expense is driven by CRO/CDMO spend and clinical trial timing - Lease accounting affects fixed obligations for lab and office space - Loan agreement accounting affects interest expense and liquidity - Asset valuation and impairment may matter for strategic transactions --- *Last updated: 2026-04-28T20:17:27.396957+00:00*